Tag Archives: AstraZeneca

Are pharmaceutical mega-mergers in the public interest?

Posted on May 2, 2014 by Barbara Arzymanow

The main reason for governments around the world to encourage the pharmaceutical industry is to support Research and Development –  R&D – with a view to the discovery of new drugs of future benefit to mankind. Commercial pharmaceutical companies have played … Continue reading →

Posted in Business, competition, Drugs, Innovation, International, Pharma, Policy, Research, Technology | Tagged , , , , , , , , , , , , , , , , , , , , | Leave a comment

Guest Blogspot: The Pharmaceutical Industry – Friend or Foe?

Posted on July 18, 2012 by Barbara Arzymanow

Recent months have seen publicity over examples of disgraceful behaviour by pharmaceutical companies. The question arises as to whether the failings have been rare and exceptional or whether they are indicative of generally low moral standards in the industry. Pharmaceutical … Continue reading →

Posted in Alcohol, Business, Drugs, Finance, GPs, Information, NHS, Obesity, Research | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Guest Blogspot: A wrong decision on UK drug pricing could seriously undermine all the good work that HM Treasury and the Department for Business, Innovation and Skills have done to encourage the UK pharmaceutical industry.

Posted on May 18, 2012 by Barbara Arzymanow

The recent local elections highlight the political dangers ahead. The current UK coalition government has lost popularity through decisions that do not all relate to austerity measures. Shortly after the General Election Andrew Lansley’s plans to increase the say of … Continue reading →

Posted in Andrew Lansley, Business, Department of Health, Drugs, Election, Global Health, Health Bill, NHS, Patient choice, Patients, Pharma, Policy, Research, Technology | Tagged , , , , , , , , , , , , , , , , , , , , , , | Leave a comment